作者：
Xiaoyan,Liu [1]
;
Jesse J,Swen [2]
;
Meta H M,Diekstra [1]
;
Epie,Boven [3]
;
Daniel,Castellano [4]
;
Hans,Gelderblom [5]
;
Ron H J,Mathijssen [6]
;
Sita H,Vermeulen [7]
;
Egbert,Oosterwijk [8]
;
Kerstin,Junker [9]
;
Max,Roessler [10]
;
Kristin,Alexiusdottir [11]
;
Asgerdur,Sverrisdottir [12]
;
Marius T,Radu [13]
;
Valentin,Ambert [14]
;
Tim,Eisen [14]
;
Anne,Warren [15]
;
Cristina,Rodríguez-Antona [16]
;
Jesus,García-Donas [17]
;
Stefan,Böhringer [18]
;
Karel K M,Koudijs [19]
;
Lambertus A L M,Kiemeney [1]
;
Brian I,Rini [8]
;
Henk-Jan,Guchelaar [20]
作者单位：
Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, the Netherlands.
[1]
Institute of Clinical Pharmacology, Qilu Hospital of Shandong University, Jinan, China.
[2]
Department of Clinical Pharmacy and Toxicology, Maastricht University Medical Center, Maastricht, the Netherlands.
[3]
Department of Medical Oncology, VU University Medical Center, Amsterdam, the Netherlands.
[4]
Oncology Department, Hospital Universitario 12 de Octubre, Madrid, Spain.
[5]
Department of Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands.
[6]
Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
[7]
Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, the Netherlands.
[8]
Department of Urology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, the Netherlands.
[9]
Clinic of Urology and Paediatric Urology, Saarland University, Homburg, Germany.
[10]
CESAR Central Office, CESAR Central European Society for Anticancer Drug Research-EWIV, Vienna, Austria.
[11]
Department of Medicine, Landspitali-University Hospital, Reykjavik, Iceland.
[12]
Department of Oncology, Landspitali-University Hospital, Reykjavik, Iceland.
[13]
University of Medicine and Pharmacy Carol Davila, Bucuresti, Romania.
[14]
Department of Oncology, Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital, Cambridge Biomedical Campus, Cambridge, United Kingdom.
[15]
Department of Pathology, Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital, Cambridge Biomedical Campus, Cambridge, United Kingdom.
[16]
Hereditary Endocrine Cancer Group, Spanish National Cancer Research Centre (CNIO) and Biomedical Network on Rare Diseases (CIBERER), Madrid, Spain.
[17]
Medical Oncology, HM Hospitales, Centro Integral Oncológico HM Clara Campal, Madrid, Spain.
[18]
Department of Medical Statistics and Bioinformatics, Leiden University Medical Center, Leiden, the Netherlands.
[19]
Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute (CCF), Cleveland, Ohio.
[20]
Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, the Netherlands. H.J.Guchelaar@lumc.nl.
[21]
DOI
10.1158/1078-0432.CCR-17-2815
PMID
29490989
发布时间
2019-12-20
换一批
换一批
